Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS)

Janmohamed, Sherief R.; Oosterhout, Marleen van; Laat, P.C.J. de; Rosmalen, Joost van; Madern, Gerard C.; Oranje, Arnold P.

doi:10.1016/j.jaad.2015.05.012

Cited by 31 publications

(37 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HSS assigns higher scores to previously established high‐risk characteristics such as size, location, association with other structural anomalies, hemangioma complications (including visual compromise and ulceration), pain, and likelihood of permanent disfigurement . Janmohamed et al recently described a scoring system, the Hemangioma Activity Score (HAS), to measure proliferative activity based on the color of the IH, and the HAS has recently been shown to have advantages over the HSS in measuring longitudinal response to therapy , but the instrument design places an emphasis on activity rather than severity. In many cases, the two scoring systems correlate, but there are some situations in which a highly proliferative hemangioma may not be severe enough to warrant therapy, such as a small active lesion on the trunk, and the HAS does not account for severity associated with potential syndromic associations.…”

Section: Discussionmentioning

confidence: 99%

Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Mull

Chamlin

Lai

et al. 2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Mull

Chamlin

Lai

et al. 2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…In this regard, QOL should be the important measurement to resolve the challenges and to evaluate the efficacy of treatment. Although several scoring systems for IH have been described over the years, there have been few studies describing QOL in IH patients and their parents [ 21 , 22 ]. In addition, only a few common instruments, like the PedsQL™, could be used to assess the QOL in IH patients before IH-QOL developed.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in children with infantile hemangioma: a case control study

Wang

Xiang

et al. 2017

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundInfantile hemangioma (IH) is the most common vascular tumor in children. It is controversial whether IHs has effects on the quality of life (QOL) in patients of whom IH poses no threat or potential for complication. Thus, we conducted this study to evaluate the q QOL in patients with IH and find the predictors of poor QOL.MethodsThe PedsQL 4.0 Genetic Core Scales and the PedsQL family information form were administered to parents of children with IH and healthy children both younger than 2-year-old. The quality-of-life instrument for IH (IH-QOL) and the PedsQL 4.0 family impact module were administered to parents of children with IH. We compared the PedsQL 4.0 Genetic Core Scales (GCIS) scores of the two groups. Multiple step-wise regression analysis was used to determine factors that influenced QOL in children with IH and their parents.ResultsExcept for physical symptom, we found no significant difference in GCIS between patient group and healthy group (P = 0.409). The internal reliability of IH-QOL was excellent with the Cronbach’s alpha coefficient for summary scores being 0.76. Multiple step-wise regression analysis showed that the predictors of poor IH-QOL total scores were hemangioma size, location, and mother’s education level. The predictors of poor FIM total scores were hemangioma location and father’s education level. The predictors of poor GCIS total scores were children’s age, hemangioma location and father’s education level.ConclusionThe findings support the feasibility and reliability of the Chinese version of IH-QOL to evaluate the QOL in children with IH and their parents. Hemangioma size, location and education level of mother are important impact factors for QOL in children with IH and their parents.

show abstract

“…For each of the standard and higher dosage groups, patient demographics (Table 1), IH clinical features (Table 2), dermatologic care, referral characteristics, and treatment specifics (Table 3) for both prospective use and retrospective use from photographs (Table 4). 11,12…”

Section: Materials S and Me Thodsmentioning

confidence: 99%

Retrospective case series of increased oral propranolol dosage for infantile hemangiomas

Huang

Mannschreck

Aggarwal

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

Infantile hemangiomas (IH) are the most common benign tumors of infancy, occurring in up to 5% of children. 1 Although oral propranolol is currently first-line therapy for IH, the optimal dosage for treatment remains controversial. The first report using oral propranolol in children with IH was published by Léauté-Labrèze et al in 2008, which showed a dramatic response to a daily dosage of 2 mg/kg. 2 In 2015, the same authors published a randomized controlled trial (RCT) that showed increased efficacy of oral propranolol for IH at a daily dose

show abstract

Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS)

Cited by 31 publications

References 7 publications

Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment

Quality of life in children with infantile hemangioma: a case control study

Retrospective case series of increased oral propranolol dosage for infantile hemangiomas

Contact Info

Product

Resources

About